# Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients

> **NCT00583622** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 13 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Carboplatin
- **DRUG:** Docetaxel
- **DRUG:** Gemcitabine
- **DRUG:** Melphalan
- **PROCEDURE:** Stem Cell Transplant

## Key facts

- **NCT ID:** NCT00583622
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-12
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Slow Accrual
- **Last updated:** 2013-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00583622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00583622, "Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00583622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*